Successful and Safe Long-term Treatment of Cerebral Aspergillosis with High-dose Voriconazole Guided by Therapeutic Drug Monitoring

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2018 Nov 11

PMID 30414213

Citations 3

Authors

Pier Giorgio Cojutti

Maria Merelli

Lorenzo Allegri

Giuseppe Damante

Matteo Bassetti

Federico Pea

Affiliations

Soon will be listed here.

Abstract

We report the case of a patient who had cerebral aspergillosis after otorhinolaryngologic surgery and who was successfully and safely treated with high-dose voriconazole (200 mg q6h) for more than 1 year thanks to a TDM-guided approach coupled with pharmacological review and with genotyping of CYP2C19 polymorphisms. The findings support the idea that personalized medicine based on TDM coupled with the need of avoiding drug-drug interactions may be helpful for maximizing the net benefit (probability of efficacy vs. probability of adverse events) of voriconazole in the management of long-term treatment of cerebral aspergillosis.

Citing Articles

Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database.

Kato H, Shiraishi C, Hagihara M, Mikamo H, Iwamoto T Sci Rep. 2024; 14(1):12519.

PMID: 38822123 PMC: 11143338. DOI: 10.1038/s41598-024-63504-y.

Voriconazole Induced Hallucinations and Visual Disturbances in a Female Child: A Case Report and Literature Review.

Zheng R, Li Y, Guo C, Pei Y, Ke Z, Huang L Front Pediatr. 2021; 9:655327.

PMID: 33968855 PMC: 8102700. DOI: 10.3389/fped.2021.655327.

Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring.

Cojutti P, Merelli M, Allegri L, Damante G, Bassetti M, Pea F Br J Clin Pharmacol. 2018; 85(1):266-269.

PMID: 30414213 PMC: 6303198. DOI: 10.1111/bcp.13789.

References

Obeng A, Egelund E, Alsultan A, Peloquin C, Johnson J . CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?. Pharmacotherapy. 2014; 34(7):703-18. PMC: 4082739. DOI: 10.1002/phar.1400. View

Ashbee H, Barnes R, Johnson E, Richardson M, Gorton R, Hope W . Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014; 69(5):1162-76. PMC: 3977608. DOI: 10.1093/jac/dkt508. View

Harding S, Sharman J, Faccenda E, Southan C, Pawson A, Ireland S . The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2017; 46(D1):D1091-D1106. PMC: 5753190. DOI: 10.1093/nar/gkx1121. View

Schwartz S, Thiel E . Cerebral aspergillosis: tissue penetration is the key. Med Mycol. 2009; 47 Suppl 1:S387-93. DOI: 10.1080/13693780802537953. View

Cojutti P, Candoni A, Forghieri F, Isola M, Zannier M, Bigliardi S . Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. Basic Clin Pharmacol Toxicol. 2015; 118(6):474-9. DOI: 10.1111/bcpt.12530. View

Moriyama B, Obeng A, Barbarino J, Penzak S, Henning S, Scott S . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016; 102(1):45-51. PMC: 5474211. DOI: 10.1002/cpt.583. View

Cojutti P, Merelli M, Allegri L, Damante G, Bassetti M, Pea F . Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring. Br J Clin Pharmacol. 2018; 85(1):266-269. PMC: 6303198. DOI: 10.1111/bcp.13789. View

Malingre M, Godschalk P, Klein S . A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine. Br J Clin Pharmacol. 2011; 74(1):205-6. PMC: 3394147. DOI: 10.1111/j.1365-2125.2011.04156.x. View

McCarthy M, Rosengart A, Schuetz A, Kontoyiannis D, Walsh T . Mold infections of the central nervous system. N Engl J Med. 2014; 371(2):150-60. PMC: 4840461. DOI: 10.1056/NEJMra1216008. View

10.

Stiefel M, Reiss T, Staege M, Rengelshausen J, Burhenne J, Wawer A . Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma. Pediatr Blood Cancer. 2005; 49(2):203-7. DOI: 10.1002/pbc.20628. View

11.

Patterson T, Thompson 3rd G, Denning D, Fishman J, Hadley S, Herbrecht R . Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4):e1-e60. PMC: 4967602. DOI: 10.1093/cid/ciw326. View

12.

Alexander S, Fabbro D, Kelly E, Marrion N, Peters J, Faccenda E . THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol. 2017; 174 Suppl 1:S272-S359. PMC: 5650666. DOI: 10.1111/bph.13877. View

13.

Lutsar I, Roffey S, Troke P . Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003; 37(5):728-32. DOI: 10.1086/377131. View

14.

Tod M, Nkoud-Mongo C, Gueyffier F . Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach. AAPS J. 2013; 15(4):1242-52. PMC: 3787231. DOI: 10.1208/s12248-013-9530-2. View

15.

Xing Y, Chen L, Feng Y, Zhou Y, Zhai Y, Lu J . Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections. BMC Infect Dis. 2017; 17(1):798. PMC: 5745890. DOI: 10.1186/s12879-017-2913-8. View

16.

Mangal N, Hamadeh I, Arwood M, Cavallari L, Samant T, Klinker K . Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults. Clin Pharmacol Ther. 2018; 104(5):957-965. PMC: 6037619. DOI: 10.1002/cpt.1012. View

17.

Elter T, Sieniawski M, Gossmann A, Wickenhauser C, Schroder U, Seifert H . Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents. 2006; 28(3):262-5. DOI: 10.1016/j.ijantimicag.2006.04.006. View

18.

Chen T, Groncy P, Javahery R, Chai R, Nagpala P, Finkelman M . Successful treatment of Aspergillus ventriculitis through voriconazole adaptive pharmacotherapy, immunomodulation, and therapeutic monitoring of cerebrospinal fluid (1→3)-β-D-glucan. Med Mycol. 2016; 55(1):109-117. DOI: 10.1093/mmy/myw118. View

19.

Alexander S, Christopoulos A, Davenport A, Kelly E, Marrion N, Peters J . THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol. 2017; 174 Suppl 1:S17-S129. PMC: 5650667. DOI: 10.1111/bph.13878. View

20.

Job K, Olson J, Stockmann C, Constance J, Enioutina E, Rower J . Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. Expert Rev Anti Infect Ther. 2016; 14(8):731-46. DOI: 10.1080/14787210.2016.1207526. View